MIM
VNDA icon

Monashee Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Monashee Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-250,000
Closed -$4.21M – 201
2018
Q1 		$4.21M Buy
+250,000
New +$4.18M 1.16% 28

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Monashee Investment Management's VNDA Position: Q2 2018 in Review

Monashee Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2018, closing a stake of 250,000 shares — an estimated $4.21M sold.

Monashee Investment Management first reported a position in VNDA in Q1 2018 and held it in 1 quarter. The position peaked at $4.21M in Q1 2018. 135 funds tracked by Wall St. Rank hold VNDA as of Q2 2018.

  • Monashee Investment Management reported no remaining Vanda Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Monashee Investment Management sold 250,000 Vanda Pharmaceuticals shares in Q2 2018, an estimated $4.21M.
  • Monashee Investment Management first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Monashee Investment Management's Vanda Pharmaceuticals position peaked at $4.21M in Q1 2018.
  • 135 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2018.

Based on Monashee Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.